World’s First Wireless Fingertip Pulse Oximeter with Masimo SET
Technology Enables Clinicians to Track and Trend Measurements through
Smart Mobile Devices
NEUCHÂTEL, Switzerland--(BUSINESS WIRE)--Jun. 22, 2015--
Masimo
(NASDAQ: MASI) today announced the CE Mark and full market release of
MightySat™ Rx fingertip pulse oximeter for clinical use in CE countries,
offering the same Masimo SET® Measure-Through Motion and Low
Perfusion™ pulse oximetry technology used in the world’s leading
hospitals.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20150622005569/en/
MightySat™ Rx fingertip pulse oximeter provides oxygen saturation (SpO2), pulse rate (PR), Perfusion Index (PI), and Pleth Variability Index (PVI®). (Photo: Business Wire)
Bluetooth®-enabled versions of MightySat Rx allow clinicians
to track and trend up to 12 hours of patient measurements on smart
mobile devices, and to share that data via standard CSV files as well as
transfer to Apple’s Health app.
MightySat Rx enables accurate noninvasive spot-checking of oxygen
saturation (SpO2) and pulse rate (PR) for adult and
paediatric patients even during motion and low perfusion. MightySat Rx
measures and displays Perfusion Index (PI), which reflects the strength
of the pulsatile signal. MightySat can also measure and display Pleth
Variability Index (PVI®), a measure of the dynamic changes in
the perfusion index that occur during one or more complete respiratory
cycle/s.
“Many clinicians around the world rely on pulse oximetry as the fifth
vital sign,” stated Joe Kiani, Founder & CEO of Masimo. “The MightySat
Rx represents a significant milestone. To deliver Masimo SET performance
in this low-power form factor took some engineering, given the precision
of our technology and SET’s computationally intensive algorithm. We
actually dropped the power consumption by nearly two orders of
magnitude. But the development effort was worth it, as we expect this
technology will empower clinicians and they will no longer have to
compromise performance for mobility.”
MightySat Rx is available in three versions for patients who weigh more
than 30 kg (66 lbs):
-
MightySat Rx – Measures and displays SpO2, PR, and PI
-
MightySat Rx, Bluetooth – Adds Bluetooth LE radio for transfer of
parameter data to Apple iOS® and select Android™ mobile
devices
-
MightySat Rx, Bluetooth and PVI
Standard features include:
-
Measure-Through Motion and Low Perfusion performance
-
Signal I.Q.® to assess measurement confidence
-
Rugged, lightweight design for operation in challenging environments
-
Long battery life–up to 15 hours with two standard AAA alkaline
batteries
-
Comfortable design with silicon finger pad to mold to patients’ fingers
Bluetooth is a registered trademark owned by Bluetooth SIG, Inc.
Apple
is a registered trademark of Apple Inc. registered in the U.S. and other
countries.
IOS is a trademark or registered trademark of Cisco in
the U.S. and other countries and is used under license.
Android is
a trademark of Google Inc.
MightySat Rx is currently unavailable in
the U.S.
About Masimo
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive
monitoring technologies that significantly improve patient care—helping
solve “unsolvable” problems. In 1995, the company debuted
Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo
SET®, which virtually eliminated false alarms and increased pulse
oximetry’s ability to help clinicians detect life-threatening events. In
2005, Masimo introduced rainbow ® Pulse CO-Oximetry™ technology,
allowing noninvasive and continuous monitoring of blood constituents
that previously required invasive procedures; total hemoglobin (SpHb®),
oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin
(SpMet®), PVI®, and perfusion index (PI), in addition to measure-through
motion SpO2, and pulse rate. In 2008, Masimo introduced Patient
SafetyNet™, a remote monitoring and wireless clinician notification
system designed to help hospitals avoid preventable deaths and injuries
associated with failure to rescue events. In 2009, Masimo introduced
rainbow® Acoustic Monitoring™, the first-ever commercially available
noninvasive and continuous monitoring of acoustic respiration rate
(RRa™). Founded in 1989, Masimo has the mission of “Improving Patient
Outcome and Reducing Cost of Care … by Taking Noninvasive Monitoring to
New Sites and Applications®.” Additional information about Masimo and
its products may be found at www.masimo.com.
@MasimoInnovates
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events
affecting us and are subject to risks and uncertainties, all of which
are difficult to predict and many of which are beyond our control and
could cause our actual results to differ materially and adversely from
those expressed in our forward-looking statements as a result of various
risk factors related to MightySat, including our belief in the
breakthrough ability of Masimo SET® pulse oximetry to measure-through
motion and low perfusion; as well as other factors discussed in the
“Risk Factors” section of our most recent reports filed with the
Securities and Exchange Commission (“SEC”), which may be obtained for
free at the SEC’s website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today’s date. We do not undertake any obligation to update, amend or
clarify these statements or the “Risk Factors” contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome
and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks
or registered trademarks of Masimo Corporation.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150622005569/en/
Source: Masimo
Masimo
Mike Drummond
949-297-7434 or 949-648-2269 (mobile)
mdrummond@masimo.com